1
|
Molina JR, Yang P, Cassivi SD, Schild SE
and Adjei AA: Non-small cell lun cancer: Epidemiology, risk
factors, treatment, and survivorship. Mayo Clin Proc. 83:584–594.
2008. View Article : Google Scholar : PubMed/NCBI
|
2
|
Nishio K, Nakamura T, Koh Y, Suzuki T,
Fukumoto H and Saijo N: Drug resistance in lung cancer. Curr Opin
Oncol. 11:109–115. 1999. View Article : Google Scholar : PubMed/NCBI
|
3
|
Thum T: Noncoding RNAs and myocardial
fibrosis. Nat Rev Cardiol. 11:655–663. 2014. View Article : Google Scholar : PubMed/NCBI
|
4
|
Kim C, Kang D, Lee EK and Lee JS: Long
noncoding RNAs and RNA-binding proteins in oxidative stress,
cellular senescence, and age-related diseases. Oxid Med Cell
Longev. 2017:20623842017. View Article : Google Scholar : PubMed/NCBI
|
5
|
Lin R, Maeda S, Liu C, Karin M and
Edgington TS: A large noncoding RNA is a marker for murine
hepatocellular carcinomas and a spectrum of human carcinomas.
Oncogene. 26:851–858. 2007. View Article : Google Scholar : PubMed/NCBI
|
6
|
Fűri I, Kalmár A, Wichmann B, Spisák S,
Schöller A, Barták B, Tulassay Z and Molnár B: Cell free DNA of
tumor origin induces a ‘Metastatic’ expression profile in HT-29
cancer cell line. PLoS One. 10:e01316992015. View Article : Google Scholar : PubMed/NCBI
|
7
|
Jin Y, Feng SJ, Qiu S, Shao N and Zheng
JH: LncRNA MALAT1 promotes proliferation and metastasis in
epithelial ovarian cancer via the PI3K-AKT pathway. Eur Rev Med
Pharmacol Sci. 21:3176–3184. 2017.PubMed/NCBI
|
8
|
Li H, Yuan X, Yan D, Li D1, Guan F, Dong
Y, Wang H, Liu X and Yang B: Long non-coding RNA MALAT1 decreases
the sensitivity of resistant glioblastoma cell lines to
temozolomide. Cell Physiol Biochem. 42:1192–1201. 2017. View Article : Google Scholar : PubMed/NCBI
|
9
|
Larne O, Hagman Z, Lilja H, Bjartell A,
Edsjö A and Ceder Y: miR-145 suppress the androgen receptor in
prostate cancer cells and correlates to prostate cancer prognosis.
Carcinogenesis. 36:858–866. 2015. View Article : Google Scholar : PubMed/NCBI
|
10
|
Chang S, Gao L, Yang Y, Tong D, Guo B, Liu
L, Li Z, Song T and Huang C: miR-145 mediates the antiproliferative
and gene regulatory effects of vitamin D3 by directly targeting
E2F3 in gastric cancer cells. Oncotarget. 6:7675–7685.
2015.PubMed/NCBI
|
11
|
Ju BL, Chen YB, Zhang WY, Yu CH, Zhu DQ
and Jin J: miR-145 regulates chemoresistance in hepatocellular
carcinoma via epithelial mesenchymal transition. Cell Mol Biol
(Noisy-le-grand). 61:12–16. 2015.PubMed/NCBI
|
12
|
Ye Z, Shen N, Weng Y, Li K, Hu L, Liao H,
An J, Liu L, Lao S and Cai S: Low miR-145 silenced by DNA
methylation promotes NSCLC cell proliferation, migration and
invasion by targeting mucin 1. Cancer Biol Ther. 16:1071–1079.
2015. View Article : Google Scholar : PubMed/NCBI
|
13
|
Lopez-Ayllon BD, Moncho-Amor V, Abarrategi
A, Ibañez de Cáceres I, Castro-Carpeño J, Belda-Iniesta C, Perona R
and Sastre L: Cancer stem cells and cisplatin-resistant cells
isolated from non-small-lung cancer cell lines constitute related
cell populations. Cancer Med. 3:1099–1111. 2014. View Article : Google Scholar : PubMed/NCBI
|
14
|
Chen YJ, Wu CY, Chang CC, Ma CJ, Li MC and
Chen CM: Nuclear Krüppel-like factor 4 expression is associated
with human skin squamous cell carcinoma progression and metastasis.
Cancer Biol Ther. 7:777–782. 2008. View Article : Google Scholar : PubMed/NCBI
|
15
|
Shi M, Cui J, Du J, Wei D, Jia Z, Zhang J,
Zhu Z, Gao Y and Xie K: A novel KLF4/LDHA signaling pathway
regulates aerobic glycolysis in and progression of pancreatic
cancer. Clin Cancer Res. 20:4370–4380. 2014. View Article : Google Scholar : PubMed/NCBI
|
16
|
Huang J, Liu K, Song D, Ding M, Wang J,
Jin Q and Ni J: Krüppel-like factor 4 promotes high-mobility group
box 1-induced chemotherapy resistance in osteosarcoma cells. Cancer
Sci. 107:242–249. 2016. View Article : Google Scholar : PubMed/NCBI
|
17
|
Fadous-Khalifé MC, Aloulou N, Jalbout M,
Hadchity J, Aftimos G, Paris F and Hadchity E: Krüppel-like factor
4: A new potential biomarker of lung cancer. Mol Clin Oncol.
5:35–40. 2016. View Article : Google Scholar : PubMed/NCBI
|
18
|
Liu MY, Li XQ, Gao TH, Cui Y, Ma N2, Zhou
Y2 and Zhang GJ: Elevated HOTAIR expression associated with
cisplatin resistance in non-small cell lung cancer patients. J
Thorac Dis. 8:3314–3322. 2016. View Article : Google Scholar : PubMed/NCBI
|
19
|
Petersen I and Warth A: Lung cancer:
Developments, concepts, and specific aspects of the new WHO
classification. J Cancer Res Clin Oncol. 142:895–904. 2016.
View Article : Google Scholar : PubMed/NCBI
|
20
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
21
|
Jia Y, Zhang W, Liu H, Peng L, Yang Z and
Lou J: Inhibition of glutathione synthesis reverses Krüppel-like
factor 4-mediated cisplatin resistance. Cancer Chemother Pharmacol.
69:377–385. 2012. View Article : Google Scholar : PubMed/NCBI
|
22
|
Minami K, Taniguchi K, Sugito N, Kuranaga
Y, Inamoto T, Takahara K, Takai T, Yoshikawa Y, Kiyama S, Akao Y
and Azuma H: MiR-145 negatively regulates Warburg effect by
silencing KLF4 and PTBP1 in bladder cancer cells. Oncotarget.
8:33064–33077. 2017. View Article : Google Scholar : PubMed/NCBI
|
23
|
Xiang Y, Zhang Y, Tang Y and Li Q: MALAT1
modulates TGF-β1-induced endothelial-to-mesenchymal transition
through downregulation of miR-145. Cell Physiol Biochem.
42:357–372. 2017. View Article : Google Scholar : PubMed/NCBI
|
24
|
Galluzzi L, Vitale I, Michels J, Brenner
C, Szabadkai G, Harel-Bellan A, Castedo M and Kroemer G: Systems
biology of cisplatin resistance: Past, present and future. Cell
Death Dis. 5:e12572014. View Article : Google Scholar : PubMed/NCBI
|
25
|
Guo F, Guo L, Li Y, Zhou Q and Li Z:
MALAT1 is an oncogenic long non-coding RNA associated with tumor
invasion in non-small cell lung cancer regulated by DNA
methylation. Int J Clin Exp Pathol. 8:15903–15910. 2015.PubMed/NCBI
|
26
|
Guo F, Jiao F, Song Z, Li S, Liu B, Yang
H, Zhou Q and Li Z: Regulation of MALAT1 expression by TDP43
controls the migration and invasion of non-small cell lung cancer
cells in vitro. Biochem Biophys Res Commun. 465:293–298. 2015.
View Article : Google Scholar : PubMed/NCBI
|
27
|
Li P, Zhang X, Wang H, Wang L, Liu T, Du
L, Yang Y and Wang C: MALAT1 is associated with poor response to
oxaliplatin-based chemotherapy in colorectal cancer patients and
promotes chemoresistance through EZH2. Mol Cancer Ther. 16:739–751.
2017. View Article : Google Scholar : PubMed/NCBI
|
28
|
Farnie G, Sotgia F and Lisanti MP: High
mitochondrial mass identifies a sub-population of stem-like cancer
cells that are chemo-resistant. Oncotarget. 6:30472–30486. 2015.
View Article : Google Scholar : PubMed/NCBI
|
29
|
Huang Z, Wu T, Liu AY and Ouyang G:
Differentiation and transdifferentiation potentials of cancer stem
cells. Oncotarget. 6:39550–39563. 2015. View Article : Google Scholar : PubMed/NCBI
|
30
|
Yu S, Cai X, Wu C, Wu L, Wang Y, Liu Y, Yu
Z, Qin S, Ma F, Thiery JP and Chen L: Adhesion glycoprotein CD44
functions as an upstream regulator of a network connecting ERK, AKT
and Hippo-YAP pathways in cancer progression. Oncotarget.
6:2951–2965. 2015. View Article : Google Scholar : PubMed/NCBI
|
31
|
Li Y, Xian M, Yang B, Ying M and He Q:
Inhibition of KLF4 by statins reverses adriamycin-induced
metastasis and cancer stemness in osteosarcoma cells. Stem Cell
Reports. 8:1617–1629. 2017. View Article : Google Scholar : PubMed/NCBI
|
32
|
Lund RJ, Huhtinen K, Salmi J, Rantala J,
Nguyen EV, Moulder R, Goodlett DR, Lahesmaa R and Carpén O: DNA
methylation and transcriptome changes associated with cisplatin
resistance in ovarian cancer. Sci Rep. 7:14692017. View Article : Google Scholar : PubMed/NCBI
|
33
|
Liu Y, Lu R, Gu J, Chen Y, Zhang X, Zhang
L, Wu H, Hua W and Zeng J: Aldehyde dehydrogenase 1A1 up-regulates
stem cell markers in benzo[a]pyrene-induced malignant
transformation of BEAS-2B cells. Environ Toxicol Pharmacol.
45:241–250. 2016. View Article : Google Scholar : PubMed/NCBI
|